Triple
T19773705
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Synagis |
E474951
|
entity |
| Predicate | wasDevelopedBy |
P73
|
FINISHED |
| Object | MedImmune |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: MedImmune | Statement: [Synagis, wasDevelopedBy, MedImmune]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: MedImmune Context triple: [Synagis, wasDevelopedBy, MedImmune]
-
A.
MedImmune
chosen
MedImmune is a biotechnology company best known as the biologics research and development arm of AstraZeneca, focusing on innovative therapies such as vaccines and monoclonal antibodies.
-
B.
Genmab
Genmab is a Danish biotechnology company specializing in the development of antibody-based cancer therapies.
-
C.
Amgen
Amgen is a leading American biopharmaceutical company known for developing innovative therapies in areas such as oncology, nephrology, and inflammatory diseases.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
AbbVie
AbbVie is a global biopharmaceutical company known for developing and marketing innovative therapies in areas such as immunology, oncology, and neuroscience.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535e450c8190a2628245ae0d0bd3 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.